PMID- 33649909
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20220321
IS  - 1432-069X (Electronic)
IS  - 0340-3696 (Linking)
VI  - 314
IP  - 1
DP  - 2022 Jan
TI  - Calcitonin gene-related peptide alleviates hypertrophic scar formation by 
      inhibiting the inflammation.
PG  - 53-60
LID - 10.1007/s00403-020-02179-7 [doi]
AB  - The present study aims to explore the roles of calcitonin gene-related peptide 
      (CGRP) in the hypertrophic scar and its underlying mechanism. The levels of CGRP 
      were determined in human hypertrophic scar and mouse cutaneous scar using ELISA 
      and Western blot. In in vivo studies, A cutaneous excision mouse model was 
      established and treated with exogenous CGRP or CGRP antagonist. In in vitro 
      studies, bone marrow-derived macrophages (BMDMs) were isolated and treated with 
      exogenous CGRP in the presence of lipopolysaccharide (LPS). qRT-PCR and Western 
      blot were applied to determine the mRNA and protein levels of scar formation and 
      inflammation-related genes, respectively. Flow cytometry was operated to 
      determine the populations of macrophages in the scar. Elevated levels of CGRP 
      were observed in the hypertrophic scar. In the cutaneous excision mouse model, 
      treatment of exogenous CGRP or CGRP antagonist-affected scar formation-related 
      genes including Col1, Tgfb1, and alpha-SMA, inflammation-related genes including 
      Il1b, Il6, Tnfa, and Ccl2, and CD45(+)F4/80(+) macrophage. In LPS-induced BMDMs, 
      treatment of exogenous CGRP also altered inflammation-related genes by regulating 
      NF-kappaB and ERK signaling pathways. The ameliorated effects of CGRP on inflammation 
      in hypertrophic scar formation are associated with its regulative effects on 
      NF-kappaB and ERK signaling pathways.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part 
      of Springer Nature.
FAU - Zhou, Yu
AU  - Zhou Y
AD  - Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, 230002, Anhui, China.
AD  - Department of Plastic Surgery, The First People's Hospital of Hefei, Hefei, 
      230002, Anhui, China.
FAU - Hua, Tianfeng
AU  - Hua T
AD  - The Laboratory of Cardiopulmonary Resuscitation and Critical Care Medicine, The 
      Second Affiliated Hospital of Anhui Medical University, Hefei, 230002, Anhui, 
      China.
AD  - Intensive Care Unit, The Second Affiliated Hospital of Anhui Medical University, 
      Hefei, 230002, Anhui, China.
FAU - Weng, Xiaojuan
AU  - Weng X
AD  - Department of Cosmetic Surgery, Yuyan Medical Cosmetology Clinic of Hefei, Hefei, 
      230002, Anhui, China.
FAU - Ma, Dameng
AU  - Ma D
AD  - Department of Cosmetic Surgery, Yuyan Medical Cosmetology Clinic of Hefei, Hefei, 
      230002, Anhui, China.
FAU - Li, Xiaojing
AU  - Li X
AD  - Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, 230002, Anhui, China. ay_lxj@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20210301
PL  - Germany
TA  - Arch Dermatol Res
JT  - Archives of dermatological research
JID - 8000462
RN  - 0 (Vasodilator Agents)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
SB  - IM
MH  - Animals
MH  - Calcitonin Gene-Related Peptide/*antagonists & 
      inhibitors/metabolism/*pharmacology
MH  - Cicatrix, Hypertrophic/*drug therapy/genetics
MH  - Disease Models, Animal
MH  - Humans
MH  - Inflammation/*drug therapy/genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Vasodilator Agents/antagonists & inhibitors/pharmacology
OTO - NOTNLM
OT  - CGRP
OT  - ERK
OT  - Hypertrophic scar
OT  - Inflammation
OT  - Inflammatory cytokines
EDAT- 2021/03/03 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/03/02 06:22
PHST- 2020/09/08 00:00 [received]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2020/10/30 00:00 [revised]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/03/02 06:22 [entrez]
AID - 10.1007/s00403-020-02179-7 [pii]
AID - 10.1007/s00403-020-02179-7 [doi]
PST - ppublish
SO  - Arch Dermatol Res. 2022 Jan;314(1):53-60. doi: 10.1007/s00403-020-02179-7. Epub 
      2021 Mar 1.